# Celanese share price today (Celanese Corporation, CE)

> Celanese Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CE · Materials · Chemicals · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/ce

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: $50.36 (+31.0% in a year)
- P/E: 21.1×, over 3.1 years
- Revenue (Jun 2026): $2.8 B (+8.7% on a year ago)
- Profit (Jun 2026): $129 M (−35.5% on a year ago)
- Operating margin: 11.0% (+1.2 points on a year ago)
- ROE: −26%, FY25
- ROIC: 5.2%, against a 6.3% cost of capital: −1.1 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Celanese share price today? Celanese Corporation's share price was $50.36 at the close on 3 November 2026. It has been moving sideways for 20 weeks. That is 2.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between $38 and $69, and at that close it sat 40% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 10 years the share price moved −25% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Celanese pay? Celanese Corporation paid $0.12 per share over the last four reported quarters. The most recent declaration was $0.03 for Jun 2026. At today's price of $50.36 that is a yield of 0.24%, based on dividends already paid, not a forecast. ## Which stock lists is Celanese on? Celanese is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Celanese profitable? Celanese Corporation earned $129 M of net profit in the Jun 2026 quarter, −35.5% on the same quarter a year earlier. The full FY25 year was a loss of $1.2 B. That is 4.7% of the quarter's revenue. The same quarter a year earlier earned $200 M. 3 of the last 12 reported quarters were loss-making. ## How much revenue does Celanese make, and is it growing? Celanese Corporation reported $2.8 B of revenue in the Jun 2026 quarter, +8.7% on the same quarter a year earlier. Over 4 years it has grown 2.8% a year on average. The last full year, FY25, came in at $9.5 B. The last four reported quarters add to $9.7 B. FY25 revenue was $9.5 B, −7.1% on the year before. Recent pace: the last four quarters grew −2.2% on average, against 2.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −2.2%, against −4.7% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Celanese keep? Celanese Corporation's operating margin was 11.0% in the Jun 2026 quarter, 1.2 percentage points higher than the same quarter a year ago. Across 5 years it has been between 8.7% and 23.9%. The latest quarter is within that range. Why the margin moved: operating margin changed +1.2 percentage points on the year while gross margin changed +1.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Celanese's profit turning into cash? Over the last 3 years, 95% of Celanese Corporation's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $1.1 B of operating cash against −$1.2 B of profit. After $343 M of spending on assets, $803 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Celanese's cash go? Celanese Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.3 B on assets over the last 3 years. Averaged over those years that is 4.7% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.3 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Celanese's P/E ratio, and how does it compare with its own history? Celanese Corporation's P/E is 21.1×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Where the price move came from: over 3 years the price moved −25.3% a year; about −2.9% a year came from earnings growth and about −22.4 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Celanese business getting better or worse? Celanese Corporation's business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −2.2% in the latest quarter, against +13.1% at its best in 12 quarters, with ROCE steady at 4.9%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Celanese earn on its capital? Celanese Corporation earned a ROE of −26% in FY25. That is up from a low of −28% in FY24. Its return on capital used (ROIC) is 1.1 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −12.1% net margin and 0.44× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −12.1% net margin × 0.44× asset turnover × 4.85× leverage (assets divided by equity) ≈ −25.8% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 5.2% − 6.3% = −1.1 percentage points. The 6.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Celanese have too much debt? Celanese Corporation has total debt of $12.4 B against shareholder equity of $4.6 B as of Jun 2026, so its debt is 2.70× its equity. Year by year, that ratio went from 0.93 in FY21 to 2.89 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Celanese shareholding pattern? 5.8% of Celanese Corporation's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Celanese from balance-sheet trouble? For Celanese Corporation, the Z-score is 1.55. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.55 is inside the danger zone, so the balance sheet is a real risk. ## How does Celanese rank in its industry? 55.6 out of 100, rank 5 of 15 in Chemicals, with 64% of the evidence available. Celanese Corporation scores 55.6 out of 100 against the 15 companies it is compared with in Chemicals, ranking 5. Relative strength against the index is -3.9%, and revenue and profit growth are weak. The four parts add up to the total exactly: 16.2 + 12.9 + 10.1 + 16.4 = 55.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Celanese compared with? Celanese ranks 5 of 15 Chemicals companies on the 4-Factor Sector Score, with 55.6 out of 100. 1. [Methanex Corporation](https://www.sectoralpha.in/us/stocks/meoh) MEOH · breaking out · Most evidence points up · 81% evidence 75.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 19.2% · Profit -64.9% · Operating margin change 20.4 points · 83% evidence Capital efficiency 17.3/25 · ROCE 11.8% · Operating margin 37.1% · 76% evidence Valuation 14.0/20 · P/E 40.4× · PEG 0.17 · 65% evidence Relative strength 20.0/20 · Lead over its industry 47% · Lead over S&P 500 24.5% · 1 year 86.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 23.8 + 17.3 + 14 + 20 = 75.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [REX American Resources Corporation](https://www.sectoralpha.in/us/stocks/rex) REX · quiet · Most evidence points up · 85% evidence 70.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.4/35 · Revenue 1.2% · Profit 100% · Operating margin change 17.3 points · 95% evidence Capital efficiency 18.4/25 · ROCE 12.9% · Operating margin 22.4% · 76% evidence Valuation 14.7/20 · P/E 11.8× · PEG 0.25 · 65% evidence Relative strength 9.6/20 · Lead over its industry 9.1% · Lead over S&P 500 -7.8% · 1 year 22.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.4 + 18.4 + 14.7 + 9.6 = 70.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Westlake Chemical Partners LP](https://www.sectoralpha.in/us/stocks/wlkp) WLKP · turning · Most evidence points up · 81% evidence 67.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 12.1% · Profit 9.4% · Operating margin change -1.3 points · 83% evidence Capital efficiency 21.7/25 · ROCE 30.4% · Operating margin 29.4% · 76% evidence Valuation 10.1/20 · P/E 13.6× · PEG 1.57 · 65% evidence Relative strength 15.5/20 · Lead over its industry 14.2% · Lead over S&P 500 -3.2% · 1 year 16.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 20.4 + 21.7 + 10.1 + 15.5 = 67.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Dow Inc.](https://www.sectoralpha.in/us/stocks/dow) DOW · turning · Too little evidence to rank firmly · 58% evidence 57.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue n/a · Profit n/a · Operating margin change 4.9 points · 45% evidence Capital efficiency 10.5/25 · ROCE 0.9% · Operating margin 6.8% · 76% evidence Valuation 10.8/20 · P/E -12.3× · PEG n/a · 15% evidence Relative strength 18.6/20 · Lead over its industry 23.9% · Lead over S&P 500 3.8% · 1 year 51.6% · 100% evidence · 3 of 12 weeks ahead Exact sum: 17.8 + 10.5 + 10.8 + 18.6 = 57.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. Celanese Corporation this page CE · turning · Evidence leans up · 64% evidence 55.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.2/35 · Revenue -2.2% · Profit n/a · Operating margin change 1.2 points · 62% evidence Capital efficiency 12.9/25 · ROCE 5.2% · Operating margin 11% · 76% evidence Valuation 10.1/20 · P/E -4.3× · PEG n/a · 15% evidence Relative strength 16.4/20 · Lead over its industry 14.6% · Lead over S&P 500 -3.9% · 1 year 21.9% · 100% evidence · 2 of 12 weeks ahead Exact sum: 16.2 + 12.9 + 10.1 + 16.4 = 55.6 · What this means: Relative strength against the index is -3.9%, and revenue and profit growth are weak. 6. [LSB Industries, Inc.](https://www.sectoralpha.in/us/stocks/lxu) LXU · turning · Evidence leans up · 64% evidence 54.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/35 · Revenue 22.1% · Profit n/a · Operating margin change -10.2 points · 62% evidence Capital efficiency 10.7/25 · ROCE 6.1% · Operating margin -1.6% · 76% evidence Valuation 9.2/20 · P/E 23.3× · PEG n/a · 15% evidence Relative strength 13.9/20 · Lead over its industry 11.8% · Lead over S&P 500 -6.6% · 1 year 29.6% · 100% evidence · 1 of 12 weeks ahead Exact sum: 20.6 + 10.7 + 9.2 + 13.9 = 54.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Green Plains Inc.](https://www.sectoralpha.in/us/stocks/gpre) GPRE · quiet · Evidence leans up · 64% evidence 53.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue -23.7% · Profit n/a · Operating margin change 16.6 points · 62% evidence Capital efficiency 12.4/25 · ROCE 8.1% · Operating margin 15.2% · 76% evidence Valuation 9.9/20 · P/E 8.7× · PEG n/a · 15% evidence Relative strength 11.2/20 · Lead over its industry 11.7% · Lead over S&P 500 -6% · 1 year 39.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 19.6 + 12.4 + 9.9 + 11.2 = 53.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Valhi, Inc.](https://www.sectoralpha.in/us/stocks/vhi) VHI · quiet · Evidence leans down · 71% evidence 45.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.1/35 · Revenue 3.4% · Profit -127.5% · Operating margin change 7 points · 83% evidence Capital efficiency 9.2/25 · ROCE -0.4% · Operating margin 6.7% · 76% evidence Valuation 10.6/20 · P/E -8.1× · PEG n/a · 15% evidence Relative strength 14.3/20 · Lead over its industry 14.2% · Lead over S&P 500 -2.7% · 1 year 5% · 100% evidence · 5 of 12 weeks ahead Exact sum: 11.1 + 9.2 + 10.6 + 14.3 = 45.2 · What this means: Relative strength against the index is -2.7%, and revenue and profit growth are weak. 9. Ascent Industries Co. ACNT · quiet · Evidence leans down · 64% evidence 43.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.0/35 · Revenue 10.5% · Profit n/a · Operating margin change 8.2 points · 62% evidence Capital efficiency 4.5/25 · ROCE -6.6% · Operating margin -0.3% · 76% evidence Valuation 11.3/20 · P/E -30.6× · PEG n/a · 15% evidence Relative strength 8.4/20 · Lead over its industry 4.1% · Lead over S&P 500 -11.1% · 1 year 8.6% · 100% evidence · 2 of 12 weeks ahead Exact sum: 19 + 4.5 + 11.3 + 8.4 = 43.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [ASP Isotopes Inc.](https://www.sectoralpha.in/us/stocks/aspi) ASPI · quiet · Evidence leans down · 61% evidence 38.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.1/35 · Revenue 100% · Profit n/a · Operating margin change 331.6 points · 62% evidence Capital efficiency 3.0/25 · ROCE -19.2% · Operating margin -667.5% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 0.3/20 · Lead over its industry -59.9% · Lead over S&P 500 -66.2% · 1 year -79.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25.1 + 3 + 10 + 0.3 = 38.4 · What this means: Earnings are strong; relative strength in its sector is -59.9% and the one-year return is -79.9%. 11. [Olin Corporation](https://www.sectoralpha.in/us/stocks/oln) OLN · basing · Evidence leans down · 64% evidence 38.3 out of 100 Growth Capital Valuation Relative
12. [Huntsman Corporation](https://www.sectoralpha.in/us/stocks/hun) HUN · quiet · Evidence leans down · 64% evidence 37.4 out of 100 Growth Capital Valuation Relative
13. [Rayonier Advanced Materials Inc.](https://www.sectoralpha.in/us/stocks/ryam) RYAM · quiet · Most evidence points down · 64% evidence 33.4 out of 100 Growth Capital Valuation Relative
14. [AdvanSix Inc.](https://www.sectoralpha.in/us/stocks/asix) ASIX · basing · Most evidence points down · 71% evidence 32.8 out of 100 Growth Capital Valuation Relative
15. [Tronox Holdings plc](https://www.sectoralpha.in/us/stocks/trox) TROX · quiet · Most evidence points down · 64% evidence 24.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Chemicals](https://www.sectoralpha.in/us/sectors/chemicals), all 15 compared on one page. ## Which companies are close to Celanese in size? Celanese is the 2nd largest of 15 Chemicals companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Dow Inc. Just below it: Methanex Corporation, Olin Corporation, Huntsman Corporation, REX American Resources Corporation and Green Plains Inc. ### Chemicals companies close in size

1. [Dow Inc.](https://www.sectoralpha.in/us/stocks/dow) $24.6 billion
2. Celanese Corporation $5.5 billion
3. [Methanex Corporation](https://www.sectoralpha.in/us/stocks/meoh) $5.4 billion
4. [Olin Corporation](https://www.sectoralpha.in/us/stocks/oln) $2 billion
5. [Huntsman Corporation](https://www.sectoralpha.in/us/stocks/hun) $1.7 billion
6. [REX American Resources Corporation](https://www.sectoralpha.in/us/stocks/rex) $1.3 billion
7. [Green Plains Inc.](https://www.sectoralpha.in/us/stocks/gpre) $986 million

[All 15 Chemicals companies, largest first](https://www.sectoralpha.in/us/sectors/chemicals#all-companies)

### Companies close in size in other industries

1. [Rithm Capital Corp.](https://www.sectoralpha.in/us/stocks/ritm) $5.3 billion · REIT - Mortgage
2. [Main Street Capital Corporation](https://www.sectoralpha.in/us/stocks/main) $5.3 billion · Asset Management
3. Celanese Corporation $5.3 billion
4. [Everus Construction Group, Inc.](https://www.sectoralpha.in/us/stocks/ecg) $5.3 billion · Engineering & Construction
5. [Spire Inc.](https://www.sectoralpha.in/us/stocks/sr) $5.3 billion · Utilities - Regulated Gas

## What else do people ask about Celanese? ### What were Celanese's latest quarterly results? Celanese Corporation reported revenue of $2.8 B and net profit of $129 M for the Jun 2026 quarter. Revenue rose 8.7% and profit fell 35.5% compared with a year earlier. Earnings per share were $1.13. The operating margin was 11.0%, 1.2 percentage points higher than a year earlier (as of 3 November 2026). ### What is Celanese's market cap? Celanese Corporation's market capitalisation is $5.5 B at a stock price of $50.36. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Celanese performing? Celanese Corporation's share price has been moving sideways for 20 weeks. In its latest quarter, revenue rose 8.7% and profit fell 35.5% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running (as of 3 November 2026). ### Will Celanese's stock price go up? This page does not forecast Celanese Corporation's stock price. What it shows instead: the stock price is $50.36, and it has been moving sideways for 20 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Does Celanese have too much debt? Yes, Celanese Corporation has a lot of debt: its debt is 2.56× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Celanese in its business cycle? Celanese Corporation's FY25 operating margin was 8.7%, against a 5-year range of 8.7% to 23.9%: the low end of its own range, which is often where recoveries start. The latest quarter was 11.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Celanese story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Celanese a stock worth studying right now? What the numbers show: Celanese Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.